Bisacodyl

CLINICAL USE


Laxative

DOSE IN NORMAL RENAL FUNCTION

Oral: 5–10 mg at nightRectal: 10 mg in the morningBowel evacuation:
  • 10 to 20 &nbsp &nbsp : mg orally at night followed by 10 mg as suppositories the next morning

    PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :361.4
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Negligible
  • %Excreted unchanged in urine &nbsp &nbsp : 30
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION

    Reconstition

    Route

    Oral, rectal

    Rate of Administration

    Comments

    OTHER INFORMATION

  • Absorption is <5% orally or rectally
  • Rapidly converted in the gut (by intestinal and bacterial enzymes) to its active, but non-absorbed, desacetyl metabolite